Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific share repurchase transaction executed on May 29, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,825,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,440.5 pence per share; lowest price paid was 1,421.5 pence per share.
- Treasury Holdings (Settled): 443,347,927 shares (8.11% of total issued share capital).
- Treasury Holdings (Including Unsettled): 448,757,927 shares (8.94% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,021,458,015 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,825,000 shares for treasury. Consequently, the percentage of shares held in treasury increased to 8.94% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (443,347,927 settled vs. 448,757,927 including unsettled).
- Confirm the denominator for voting rights calculations is 5,021,458,015 shares.
- Check the price range paid (1,421.5 to 1,440.5 pence) against market prices on May 29, 2012.
- Note that this filing does not contain operational or financial performance data.